Spruce Biosciences Reassesses Strategy After CAH Trials Reveal Tildacerfont Challenges

Spruce Biosciences Reevaluates Clinical Strategy Following CAH Trials Outcomes

Spruce Biosciences, Inc., a biopharmaceutical company specializing in treatments for neurological and endocrine disorders, recently announces the topline results from its clinical trials examining the efficacy of tildacerfont in treating congenital adrenal hyperplasia (CAH). The results from the CAHmelia-204 and CAHptain-205 trials reveal significant challenges in demonstrating the drug's effectiveness. In the CAHmelia-204 Phase 2b trial, which included 100 adult participants, the primary efficacy endpoint was not met, showing only a marginal placebo-adjusted reduction in hydrocortisone equivalent doses after 24 weeks of treatment. Despite a high treatment adherence rate of approximately 98%, the study indicates that higher doses and more frequent administration may be necessary to achieve the desired clinical outcomes.

In the CAHptain-205 study, which was a shorter 4-week open-label trial, various dosing regimens of tildacerfont were explored. While some trends suggested larger reductions in androstenedione levels with increased dosing, the study did not provide definitive evidence of therapeutic benefit. Importantly, both studies reported that tildacerfont was generally well tolerated, with no serious adverse events recorded. Dr. Javier Szwarcberg, a key figure in the trials, expressed gratitude towards the CAH community for their participation and highlighted the insights gained from these studies, which will be instrumental in guiding future approaches to CAH management.

In light of these findings, Spruce Biosciences announces plans to discontinue both clinical trials to conserve financial resources while reassessing its strategic options. This decision reflects a broader commitment to maximizing shareholder value by shifting focus away from tildacerfont and exploring other potential treatment avenues for patients with unmet medical needs. The company emphasizes that valuable data collected from nearly 400 CAH patients will continue to inform ongoing research efforts, with plans to present the findings at conferences in 2025.

Spruce's recent developments underline the complexities of drug development in the biopharmaceutical sector, particularly in addressing rare endocrine disorders such as CAH. As the company pivots away from tildacerfont, it faces the challenge of identifying new therapeutic targets while navigating the financial implications of trial discontinuation. The ongoing commitment to patient-centered research and community engagement remains a core focus as Spruce seeks to fulfill its mission of delivering innovative treatments for those in need.